Exelixis

Mar 04, 2020

$770M Thyroid Cancer Drugs Market Insights, 2015-2030

Oct 14, 2019

Global Kidney Cancer Drugs Industry

Sep 19, 2018

Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma

Aug 13, 2018

Kidney Cancer Drugs Market to 2022 By Therapeutic Class, Pharmacologic Class & Country - Key Players are Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, and Exelixis

Jul 27, 2018

Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols

May 02, 2018

Free Research Reports on These Biotech Stocks -- Exelixis, INSYS Therapeutics, Intellia Therapeutics, and Intercept Pharma

Feb 13, 2018

Cabozantinib shows significant activity in the first line for differentiated thyroid cancer

Jan 15, 2018

Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®

Dec 28, 2017

Quotidian Technical Highlights on Selected Biotech Stocks -- Clovis Oncology, Exelixis, Celgene, and BioCryst Pharma

Nov 21, 2017

Biotech Stock Performance Review -- BioCryst Pharma, Celgene, Exelixis, and Geron

Oct 19, 2017

Breakfast Technical Briefing on Biotech Stocks -- Coherus Biosciences, Exelixis, Geron, and Grifols

Jun 21, 2017

Biopharma Stock Breakouts With Significant Developments and Market Activity